Literature DB >> 33522893

COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue.

Xi Yongzhi1.   

Abstract

SARS-CoV-2 has claimed 2,137,908 lives in more than a year. Some COVID-19 patients experience sudden and rapid deterioration with the onset of fatal cytokine storm syndrome (CSS), which have increased interest in CSS's mechanisms, diagnosis and therapy. Although the prototypic concept of CSS was first proposed 116 years ago, we have only begun to study and understand CSS for less than 30 years. Actually, diseases under CSS umbrella include familial/primary and secondary hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), infection-associated hemophagocytic syndrome, cytokine release syndrome (CRS), and cytokine storm (CS). Hematologic malignancies and autoimmune diseases that cause CSS are named malignancy-associated hemophagocytic syndrome (MAHS) and MAS, respectively. In-depth research on the pathogenesis of HLH/CSS has greatly increased the number of patients that were able to be definitively diagnosed with HLH/CSS. However, it should be emphasized that HLH/CSS diagnosis is difficult at the early stages due to the non-specific clinical signs and symptoms, which tends to result in missed and incorrect diagnoses. Therefore, clinicians should not only possess extensive clinical experience to ensure high sensitivity to the characteristics of HLH/CSS but must also be familiar with HLH-2004/2009 diagnostic criteria, and HScore methods. The paper concisely comment evolution of CSS classifications, cytokines associated with CSS, evolution of CSS diagnostic criteria and importance of the correct identification of hemophagocytes in diagnosing CSS, which is timely and may benefit clinicians familiar HLH-2004/2009 diagnostic criteria, and HScore methods. In addition, clinicians must also understand that there are some limitations to these diagnostic criteria. Abbreviations: aBMT: autologous bone marrow transplantation; CAR-T: chimeric antigen receptor-engineered T-cell; COVID-19: coronavirus disease 2019; CSS: cytokine storm syndrome; HLH: hemophagocytic lymphohistiocytosis; MAS: macrophage activation syndrome; CRS: cytokine release syndrome; CS: cytokine storm; MAHS: malignancy-associated hemophagocytic syndrome; IAHS: infection-associated hemophagocytic syndrome; fHLH/pHLH: familial/primary hemophagocytic lymphohistiocytosis; sHLH: secondary hemophagocytic lymphohistiocytosis; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; TCR-T, T-cell receptor-engineered T-cell.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; cytokine storm syndrome; familial/primary hemophagocytic lymphohistiocytosis; secondary hemophagocytic lymphohistiocytosis

Mesh:

Substances:

Year:  2021        PMID: 33522893      PMCID: PMC7894425          DOI: 10.1080/22221751.2021.1884503

Source DB:  PubMed          Journal:  Emerg Microbes Infect        ISSN: 2222-1751            Impact factor:   7.163


  45 in total

1.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

Review 2.  Severe Covid-19.

Authors:  David A Berlin; Roy M Gulick; Fernando J Martinez
Journal:  N Engl J Med       Date:  2020-05-15       Impact factor: 91.245

Review 3.  New insights into the structure and function of chemokine receptor:chemokine complexes from an experimental perspective.

Authors:  Martin Gustavsson
Journal:  J Leukoc Biol       Date:  2020-01-22       Impact factor: 4.962

Review 4.  How I treat hemophagocytic lymphohistiocytosis.

Authors:  Michael B Jordan; Carl E Allen; Sheila Weitzman; Alexandra H Filipovich; Kenneth L McClain
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

Review 5.  Preliminary predictive criteria for COVID-19 cytokine storm.

Authors:  Roberto Caricchio; Marcello Gallucci; Chandra Dass; Xinyan Zhang; Stefania Gallucci; David Fleece; Michael Bromberg; Gerard J Criner
Journal:  Ann Rheum Dis       Date:  2020-09-25       Impact factor: 19.103

6.  Childhood tuberculosis presenting with haemophagocytic syndrome.

Authors:  Tarun Verma; Sameer Aggarwal
Journal:  Indian J Hematol Blood Transfus       Date:  2011-10-08       Impact factor: 0.900

Review 7.  A New Venue of TNF Targeting.

Authors:  Sophie Steeland; Claude Libert; Roosmarijn E Vandenbroucke
Journal:  Int J Mol Sci       Date:  2018-05-11       Impact factor: 5.923

8.  COVID-19: consider cytokine storm syndromes and immunosuppression.

Authors:  Puja Mehta; Daniel F McAuley; Michael Brown; Emilie Sanchez; Rachel S Tattersall; Jessica J Manson
Journal:  Lancet       Date:  2020-03-16       Impact factor: 79.321

Review 9.  Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.

Authors:  Yvan Jamilloux; Thomas Henry; Alexandre Belot; Sébastien Viel; Maxime Fauter; Thomas El Jammal; Thierry Walzer; Bruno François; Pascal Sève
Journal:  Autoimmun Rev       Date:  2020-05-04       Impact factor: 9.754

10.  COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

Authors:  Georg Schett; Michael Sticherling; Markus F Neurath
Journal:  Nat Rev Immunol       Date:  2020-05       Impact factor: 53.106

View more
  14 in total

1.  Predicting the Disease Severity of Virus Infection.

Authors:  Xin Qi; Li Shen; Jiajia Chen; Manhong Shi; Bairong Shen
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Chasing the Ghost: Hyperinflammation Does Not Cause Sepsis.

Authors:  Leland Shapiro; Sias Scherger; Carlos Franco-Paredes; Amal A Gharamti; David Fraulino; Andrés F Henao-Martinez
Journal:  Front Pharmacol       Date:  2022-06-23       Impact factor: 5.988

3.  Glycyrrhetinic acid: A potential drug for the treatment of COVID-19 cytokine storm.

Authors:  Huawei Li; Jia You; Xi Yang; Yuanfeng Wei; Lingnan Zheng; Yaqin Zhao; Ying Huang; Zhao Jin; Cheng Yi
Journal:  Phytomedicine       Date:  2022-05-13       Impact factor: 6.656

Review 4.  Implications of SARS-CoV-2 Infection in Systemic Juvenile Idiopathic Arthritis.

Authors:  Laura Marinela Ailioaie; Constantin Ailioaie; Gerhard Litscher
Journal:  Int J Mol Sci       Date:  2022-04-12       Impact factor: 6.208

5.  Incidence, characteristics and clinical profile of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with pre-existing primary immune thrombocytopenia (ITP) in Spain.

Authors:  María E Mingot-Castellano; Patricia Alcalde-Mellado; Cristina Pascual-Izquierdo; Gloria Perez Rus; Aida Calo Pérez; María P Martinez; Francisco J López-Jaime; Lorena Abalo Perez; José R Gonzalez-Porras; Fernanda López Fernández; Isabel S Caparrós Miranda; Tomás J González-López; María E Moreno Beltrán; Rebeca Rubio Escuin; Reyes Jimenez Bárcenas
Journal:  Br J Haematol       Date:  2021-05-15       Impact factor: 8.615

6.  Clinical Features and Outcomes of Coronavirus Disease 2019 Among People With Human Immunodeficiency Virus in the United States: A Multicenter Study From a Large Global Health Research Network (TriNetX).

Authors:  George A Yendewa; Jaime Abraham Perez; Kayla Schlick; Heather Tribout; Grace A McComsey
Journal:  Open Forum Infect Dis       Date:  2021-06-01       Impact factor: 3.835

7.  Clinical features and predictors of mortality among hospitalized patients with COVID-19 in Niger.

Authors:  Patrick D M C Katoto; Issoufou Aboubacar; Batouré Oumarou; Eric Adehossi; Blanche-Philomene Melanga Anya; Aida Mounkaila; Adamou Moustapha; El Khalef Ishagh; Gbaguidi Aichatou Diawara; Biey Joseph Nsiari-Muzeyi; Tambwe Didier; Charles Shey Wiysonge
Journal:  Confl Health       Date:  2021-12-14       Impact factor: 2.723

8.  Hemophagocytosis, hyper-inflammatory responses, and multiple organ damages in COVID-19-associated hyperferritinemia.

Authors:  Guiying Dong; Jianbo Yu; Weibo Gao; Wei Guo; Jihong Zhu; Tianbing Wang
Journal:  Ann Hematol       Date:  2021-12-04       Impact factor: 3.673

9.  SARS-CoV-2 infection in people with pre-existing liver disease: Further research is warranted.

Authors:  Henu Kumar Verma; Lvks Bhaskar
Journal:  World J Gastroenterol       Date:  2021-12-07       Impact factor: 5.742

10.  Severe COVID-19 Shares a Common Neutrophil Activation Signature with Other Acute Inflammatory States.

Authors:  Lena F Schimke; Alexandre H C Marques; Gabriela Crispim Baiocchi; Caroline Aliane de Souza Prado; Dennyson Leandro M Fonseca; Paula Paccielli Freire; Desirée Rodrigues Plaça; Igor Salerno Filgueiras; Ranieri Coelho Salgado; Gabriel Jansen-Marques; Antonio Edson Rocha Oliveira; Jean Pierre Schatzmann Peron; Gustavo Cabral-Miranda; José Alexandre Marzagão Barbuto; Niels Olsen Saraiva Camara; Vera Lúcia Garcia Calich; Hans D Ochs; Antonio Condino-Neto; Katherine A Overmyer; Joshua J Coon; Joseph Balnis; Ariel Jaitovich; Jonas Schulte-Schrepping; Thomas Ulas; Joachim L Schultze; Helder I Nakaya; Igor Jurisica; Otávio Cabral-Marques
Journal:  Cells       Date:  2022-03-01       Impact factor: 7.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.